Pharmaceutical packaging manufacturers are being urged to begin testing recyclable, high-barrier materials well before the European Union’s Packaging and Packaging Waste Regulation requirements take full effect.

Although the PPWR includes targeted exemptions for some pharmaceutical and medical packaging, industry experts warn that long validation cycles, strict safety requirements and complex regulatory approvals mean companies cannot wait until the final compliance deadlines to act.

The regulation will generally apply from 12 August 2026, while further requirements covering recyclability, packaging minimization and recycled content will be introduced gradually through 2030 and beyond.

Long Validation Cycles Increase Compliance Pressure

Changing a primary pharmaceutical packaging material is significantly more complex than changing packaging in most consumer sectors.

According to industry experts, a new material may require:

• regulatory variation filings
• stability testing
• sterilization validation
• transport testing
• shelf-life assessment
• compatibility studies

Real-time stability testing alone can take between one and three years.

For this reason, pharmaceutical companies are being encouraged to begin evaluating recyclable laminates, monomaterial structures and alternative high-barrier materials now rather than waiting for the 2030 requirements.

Exemptions Do Not Remove All Obligations

The PPWR provides exemptions for some direct-contact packaging used for medicinal products and medical devices where specific materials are necessary to protect product safety, quality or effectiveness.

However, these exemptions are limited.

Industry representatives caution that companies should not assume all pharmaceutical packaging falls outside the regulation.

Secondary packaging, in particular, is more likely to remain subject to requirements covering:

• packaging reduction
• recyclability
• recycled content
• labeling
• compliance documentation

Even where an exemption may apply, manufacturers may still need to provide technical evidence explaining why a particular packaging structure is necessary.

Documentation Becomes a Major Challenge

One of the most immediate compliance issues is the collection of technical data across pharmaceutical supply chains.

Companies will need to obtain material declarations, testing records and supporting documentation from numerous suppliers.

This process is particularly difficult because packaging components may come from several different material producers, converters and specialized manufacturers.

The European Federation of Pharmaceutical Industries and Associations has also raised concerns about uncertainty surrounding the interaction between PPWR labeling requirements and existing pharmaceutical legislation.

Because medicine packaging changes often require regulatory approval, sector-specific guidance may be needed to prevent conflicting requirements.

Recyclability Must Be Balanced with Patient Safety

For pharmaceutical packaging, sustainability cannot compromise sterility, barrier performance or product protection.

Many healthcare products rely on specialized multilayer materials, coatings and seals to protect against moisture, oxygen, contamination and physical damage.

Replacing these materials with simpler recyclable structures may improve circularity, but only if the new packaging can still withstand manufacturing, sterilization, distribution and long-term storage.

Industry suppliers are therefore adopting a risk-based approach in which patient safety and regulatory compliance remain the primary requirements, while sustainability improvements are introduced where technically feasible.

Monomaterial and PCR Solutions Gain Attention

Packaging developers are increasingly exploring designs that improve recyclability without reducing performance.

Current development priorities include:

• monomaterial thermoformed blister packaging
• lighter packaging structures
• recyclable high-barrier laminates
• post-consumer recycled plastic
• reduced material use
• lower levels of substances of concern

Plastic Ingenuity, for example, has developed a pharmaceutical clamshell containing 75% post-consumer recycled PET, supported by lifecycle assessment, material trials and performance testing.

Such projects demonstrate how recycled content may be introduced when material performance, sterilization compatibility and product protection can be validated.

Recyclability Requirements Will Tighten Over Time

The PPWR will introduce its technical requirements in stages.

Industry experts expect:

• design-for-recycling criteria from 2028
• broader recyclability requirements from 2030
• packaging minimization provisions from 2030
• recycled-content requirements for covered plastic packaging
• recycled-at-scale requirements from 2035
• stricter recyclability grades from 2038

Packaging that does not meet the required recyclability grade may eventually lose access to the EU market unless an exemption applies.

Early Testing Becomes Essential

The pharmaceutical packaging industry is therefore moving toward earlier material testing, closer supplier cooperation and more detailed compliance documentation.

Rather than treating sustainability as a separate material substitution exercise, companies are increasingly integrating recyclability and circularity into the full package-development and validation process.

As PPWR implementation progresses, pharmaceutical manufacturers that begin testing materials now will be better positioned to meet future requirements without disrupting product availability or compromising patient safety.

Last Updated on 28/07/2026 by Jota Machinery